Work

Enhancing T cell therapy through TCR-signaling-responsive nanoparticle drug delivery

Year: 2018

Type: article

Source: Nature Biotechnology

DOI: 10.1038/nbt.4181

Authors: Li Tang, Yiran Zheng, Mariane Bandeira Melo, Llian Mabardi, Ana P Castaño, Yu-Qing Xie, Na Li, Sagar B Kudchodkar, Hing C Wong, Emily K Jeng, Marcela V Maus, Darrell J Irvine

Institutions: Koch Institute for Integrative Cancer Research At MIT, Massachusetts Institute of Technology, Massachusetts General Hospital, École Polytechnique Fédérale de Lausanne, The Wistar Institute, Altor BioScience (United States), Harvard University, Howard Hughes Medical Institute, Ragon Institute of MGH, MIT and Harvard

Language: English

Topic: CAR-T cell therapy research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: National Science Foundation, Cancer Research Institute, Melanoma Research Alliance, Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Biltema Foundation, Agency for Science, Technology and Research, Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung, Fondation ISREC, National Institutes of Health, National Cancer Institute

Awards: G2360436881, G4193939855, Immunoengineering through responsive nanoparticle drug delivery, G4966013024, Targeting immunosuppression blockade to T cells for cancer immunotherapy, Designer antigen receptors to re-direct T cells to the NY-ESO-1 tumor antigen, Cancer Center Support (Core) Grant

OpenAlex ID: W2836754285

FWCI: 26.03

Cites: 50

Cited by: 677

Related to: 10